{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Drug+Use&page=2",
    "query": {
      "condition": "Multiple Drug Use",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Drug+Use&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T10:05:43.430Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01989156",
      "title": "Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Smoking"
      ],
      "interventions": [
        {
          "name": "THS 2.2 Menthol (mTHS 2.2)",
          "type": "OTHER"
        },
        {
          "name": "Menthol Conventional Cigarette (mCC)",
          "type": "OTHER"
        },
        {
          "name": "Smoking Abstinence (SA)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Philip Morris Products S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2013-12",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 2,
      "location_summary": "Daytona Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01989156"
    },
    {
      "nct_id": "NCT04261504",
      "title": "Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Drug Use"
      ],
      "interventions": [
        {
          "name": "IBMT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "RT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Texas Tech University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "23 Years",
        "sex": "ALL",
        "summary": "18 Years to 23 Years"
      },
      "enrollment_count": 70,
      "start_date": "2019-04-19",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04261504"
    },
    {
      "nct_id": "NCT02477891",
      "title": "Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Gilroy",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477891"
    },
    {
      "nct_id": "NCT01081275",
      "title": "Improving Hand Use in Multiple Sclerosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "CI Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "CAM treatments",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Multiple Sclerosis Society",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 66,
      "start_date": "2010-02",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-15",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081275"
    },
    {
      "nct_id": "NCT04832932",
      "title": "The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19 Vaccines"
      ],
      "interventions": [
        {
          "name": "COVID-19 vaccines",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mebo Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2021-01-05",
      "completion_date": "2025-01-05",
      "has_results": false,
      "last_update_posted_date": "2024-01-26",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Vonore, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Vonore",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04832932"
    },
    {
      "nct_id": "NCT06025396",
      "title": "Multiple Ascending Dose Study of TMP-301 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Use Disorder",
        "Substance Use Disorders",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Cohort 1 - TMP-301",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cohort 2 - TMP-301",
          "type": "DRUG"
        },
        {
          "name": "Cohort 3 - TMP-301",
          "type": "DRUG"
        },
        {
          "name": "Cohort 4 - TMP-301",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tempero Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-01-06",
      "completion_date": "2024-01-02",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06025396"
    },
    {
      "nct_id": "NCT04080180",
      "title": "SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "Contingency Management",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Brief Motivational Interviewing + Substance Free Activities + Mindfulness",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Karen Derefinko, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2022-02-01",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04080180"
    },
    {
      "nct_id": "NCT04356339",
      "title": "US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Interferon-beta-1b (BETASERON, BAY 86-5046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-11-24",
      "completion_date": "2021-11-11",
      "has_results": false,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04356339"
    },
    {
      "nct_id": "NCT07595367",
      "title": "Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Reaction (IgA) Vasculitis"
      ],
      "interventions": [
        {
          "name": "BBD-1 Multi target Immune Enhancement Targeting Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qifeng Zhang",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2026-08-10",
      "completion_date": "2028-08-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07595367"
    },
    {
      "nct_id": "NCT02075138",
      "title": "Grass Observational Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Grass Allergy",
        "Rhinoconjunctivitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Circassia Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 109,
      "start_date": "2014-04",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-08",
      "last_synced_at": "2026-09-03T10:05:43.430Z",
      "location_count": 5,
      "location_summary": "Washington D.C., District of Columbia • Normal, Illinois • Sylvania, Ohio + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Sylvania",
          "state": "Ohio"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02075138"
    }
  ]
}